Austin Health

Title
Clinical, biochemical and genetic characteristics of MOGS-CDG: a rare congenital disorder of glycosylation.
Publication Date
2022-07-05
Author(s)
Shimada, Shino
Ng, Bobby G
White, Amy L
Nickander, Kim K
Turgeon, Coleman
Liedtke, Kristen L
Lam, Christina T
Font-Montgomery, Esperanza
Lourenco, Charles M
He, Miao
Peck, Dawn S
Umana, Luis A
Uhles, Crescenda L
Haynes, Devon
Wheeler, Patricia G
Bamshad, Michael J
Nickerson, Deborah A
Cushing, Tom
Gates, Ryan
Gomez-Ospina, Natalia
Byers, Heather M
Scalco, Fernanda B
Martinez, Noelia N
Sachdev, Rani
Smith, Lacey
Poduri, Annapurna
Malone, Stephen
Harris, Rebekah V
Scheffer, Ingrid E
Rosenzweig, Sergio D
Adams, David R
Gahl, William A
Malicdan, May Christine V
Raymond, Kimiyo M
Freeze, Hudson H
Wolfe, Lynne A
Subject
central nervous system diseases
diagnosis
glycomics
human genetics
sequence analysis, DNA
Type of document
Journal Article
OrcId
http://orcid.org/0000-0001-5525-7362
http://orcid.org/0000-0003-0649-848X
http://orcid.org/0000-0001-8226-615X
http://orcid.org/0000-0002-2648-7828
http://orcid.org/0000-0002-2311-2174
http://orcid.org/0000-0003-1697-6959
DOI
10.1136/jmedgenet-2021-108177
Abstract
To summarise the clinical, molecular and biochemical phenotype of mannosyl-oligosaccharide glucosidase-related congenital disorders of glycosylation (MOGS-CDG), which presents with variable clinical manifestations, and to analyse which clinical biochemical assay consistently supports diagnosis in individuals with bi-allelic variants in MOGS. Phenotypic characterisation was performed through an international and multicentre collaboration. Genetic testing was done by exome sequencing and targeted arrays. Biochemical assays on serum and urine were performed to delineate the biochemical signature of MOGS-CDG. Clinical phenotyping revealed heterogeneity in MOGS-CDG, including neurological, immunological and skeletal phenotypes. Bi-allelic variants in MOGS were identified in 12 individuals from 11 families. The severity in each organ system was variable, without definite genotype correlation. Urine oligosaccharide analysis was consistently abnormal for all affected probands, whereas other biochemical analyses such as serum transferrin analysis was not consistently abnormal. The clinical phenotype of MOGS-CDG includes multisystemic involvement with variable severity. Molecular analysis, combined with biochemical testing, is important for diagnosis. In MOGS-CDG, urine oligosaccharide analysis via matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry can be used as a reliable biochemical test for screening and confirmation of disease.
Link
Citation
Journal of medical genetics 2022; online first: 5 July
Jornal Title
Journal of medical genetics

Files:

NameSizeformatDescriptionLink